- Markets
- Healthcare
- SYNCOMF
SYNCOMF
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Syncom Formulations (India) To Commence Manufacturing, Marketing Of Generic Products
Aug 30 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
SYNCOM FORMULATIONS (INDIA) - TO COMMENCE MANUFACTURING, MARKETING OF GENERIC PRODUCTS
Further company coverage: SYFI.NS
(([email protected];))
Aug 30 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
SYNCOM FORMULATIONS (INDIA) - TO COMMENCE MANUFACTURING, MARKETING OF GENERIC PRODUCTS
Further company coverage: SYFI.NS
(([email protected];))
Syncom Formulations (India) Re-Appoints Kedarmal Shankarlal Bankda As Chairman
Aug 12 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
RE-APPOINTS KEDARMAL SHANKARLAL BANKDA AS CHAIRMAN
Further company coverage: SYFI.NS
(([email protected];))
Aug 12 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
RE-APPOINTS KEDARMAL SHANKARLAL BANKDA AS CHAIRMAN
Further company coverage: SYFI.NS
(([email protected];))
Syncom Formulations (India) Commences Commercial Production In Pithampur Plant
Aug 21 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
COMMENCED COMMERCIAL PRODUCTION IN PITHAMPUR PLANT
Source text for Eikon: ID:nBSE6gLJQY
Further company coverage: SYFI.NS
(([email protected];))
Aug 21 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
COMMENCED COMMERCIAL PRODUCTION IN PITHAMPUR PLANT
Source text for Eikon: ID:nBSE6gLJQY
Further company coverage: SYFI.NS
(([email protected];))
Syncom Formulations (India) June-Quarter Consol Profit Rises
Aug 14 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
JUNE-QUARTER CONSOL PROFIT 44 MILLION RUPEES VERSUS PROFIT 38.7 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 598.4 MILLION RUPEES VERSUS 514 MILLION RUPEES
Source text for Eikon: ID:nBSE5Bwbv7
Further company coverage: SYFI.NS
(([email protected];;))
Aug 14 (Reuters) - Syncom Formulations (India) Ltd SYFI.NS:
JUNE-QUARTER CONSOL PROFIT 44 MILLION RUPEES VERSUS PROFIT 38.7 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 598.4 MILLION RUPEES VERSUS 514 MILLION RUPEES
Source text for Eikon: ID:nBSE5Bwbv7
Further company coverage: SYFI.NS
(([email protected];;))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Syncom Formulations do?
Syncom Formulations (India) Ltd. specializes in manufacturing and marketing a wide range of pharmaceutical products in various dosage forms such as tablets, capsules, liquids, injectibles, and herbal products.
Who are the competitors of Syncom Formulations?
Syncom Formulations major competitors are Jagsonpal Pharma, Beta Drugs, Bliss GVS Pharma, Novartis, Lincoln Pharma, Indoco Remedies, Shivalik Rasayan. Market Cap of Syncom Formulations is ₹1,677 Crs. While the median market cap of its peers are ₹1,497 Crs.
Is Syncom Formulations financially stable compared to its competitors?
Syncom Formulations seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Syncom Formulations pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Syncom Formulations latest dividend payout ratio is 14.05% and 3yr average dividend payout ratio is 14.05%
How has Syncom Formulations allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments, Accounts Receivable
How strong is Syncom Formulations balance sheet?
Balance sheet of Syncom Formulations is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Syncom Formulations improving?
Yes, profit is increasing. The profit of Syncom Formulations is ₹39.15 Crs for TTM, ₹25.31 Crs for Mar 2024 and ₹20.07 Crs for Mar 2023.
Is the debt of Syncom Formulations increasing or decreasing?
Yes, The debt of Syncom Formulations is increasing. Latest debt of Syncom Formulations is ₹2.36 Crs as of Sep-24. This is greater than Mar-24 when it was -₹63 Crs.
Is Syncom Formulations stock expensive?
Syncom Formulations is not expensive. Latest PE of Syncom Formulations is 42.84, while 3 year average PE is 49.54. Also latest EV/EBITDA of Syncom Formulations is 35.91 while 3yr average is 47.36.
Has the share price of Syncom Formulations grown faster than its competition?
Syncom Formulations has given better returns compared to its competitors. Syncom Formulations has grown at ~43.87% over the last 7yrs while peers have grown at a median rate of 8.76%
Is the promoter bullish about Syncom Formulations?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Syncom Formulations is 50.57% and last quarter promoter holding is 50.57%.
Are mutual funds buying/selling Syncom Formulations?
There is Insufficient data to gauge this.